All In Biotech

Drug Trial Radar · NCT04701476

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

May 20, 2021

Primary completion

Mar 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Teclison Ltd.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

Conditions

  • Colorectal Cancer; Lung Cancer

Interventions

  • TATE and pembrolizumabDrug

    All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.

  • TAS-102 pillDrug

    The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.

  • Regorafenib PillDrug

    As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival for the mCRC cohortTime frame: 24 months
  2. Overall Response Rate (ORR) for the NSCLC cohortTime frame: within 24 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Irvine Medical Center

    Orange, California · Recruiting

  • China Medical University Hsinchu Hospital

    Hsinchu, Taiwan · Recruiting

  • Chung Shan Medical University Hospital

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.